BioCryst Pharmaceuticals, Inc. — Earnings Quality Grade B
BCRX · Healthcare
Generally healthy
Screening Summary
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 45 days, change -19 days YoY
AR growth 35.1% vs revenue growth 94.1%
Revenue 94.1%, CFFO 767.8%. Cash follows revenue
Expense Quality
Inventory -33.3% vs COGS 55.5%. Normal
CapEx growth 119.6% vs revenue 94.1%. Normal
SG&A/Gross Profit = 40.7%. Normal
Gross margin 97.8%, change +0.5pp. Stable
Cash Flow Quality
CFFO/NI = 1.32. Profits backed by cash
FCF $0.3B, FCF/NI = 1.31
Accruals ratio = -16.2%. Low accruals
Cash $0.3B covers 63% of debt $0.4B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = 1.3x. Healthy
Other assets 4.7% vs revenue 94.1%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
M-Score = -2.20 (grey zone)
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25